ストックスクリーナーアプリを入手
13.53
0.18%
-0.0261
Organon Co (OGN) 最新ニュース
Organon to present VTAMA cream data at pediatric dermatology meeting By Investing.com - Investing.com Canada
Organon’s VTAMA data heads to pediatric dermatology meeting - Stock Titan
Sun Pharma's $11.8 bn Organon buy drives India's M&A value to 4-year high - Business Standard
What Sparked Organon's Recent Stock Surge - Kavout | AI
OGNOrganon & Co Volatility & Greeks - Finviz
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
OGN Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesShare Repurchase Impact - dars.gov.et
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets? - Insider Monkey
Organon & Co. Actuals & Estimates (NYSE:OGN) - TradingView
Organon & Co updates strategic focus, shares watched on NYSE - AD HOC NEWS
Organon wins FDA nod to expand TOFIDENCE use in severe CRS & COVID-19 - MSN
Class Action Lawsuit Filed: Organon & Co. (OGN)Join by July 22, 2025Contact Levi & Korsinsky - The National Law Review
Enterprise value to EBITDA forward of Organon & Co. – MUN:7XP - TradingView
Price to earnings forward of Organon & Co. – NYSE:OGN - TradingView
Price to earnings forward of Organon & Co. – LSE:0A9W - TradingView
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada - MSN
Mayne Pharma appoints former Organon & Co executive Meghan Rivera to board - MSN
(OGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of Organon & Co. – NYSE:OGN - TradingView
Enterprise value to EBITDA forward of Organon & Co. – LSE:0A9W - TradingView
Enterprise value to revenue forward of Organon & Co. – NYSE:OGN - TradingView
Shareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Organon & Co. (OGN) InvestorsLead Plaintiff Deadline on July 22, 2025 - The National Law Review
OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
FINAL OGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Org - The National Law Review
Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Enterprise value to EBIT forward of Organon & Co. – LSE:0A9W - TradingView
Organon & Co updates earnings timing, shares watched by health care investors - Ad-hoc-news.de
Organon celebrates 5 years of expanding healthcare access - Manila Standard
Organon & Co (OGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organon & Co stock hits 52-week high at $13.49 - Investing.com UK
Organon & Co stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? - TradingView
OGN Forecast — Price Target — Prediction for 2027 - TradingView
Gorvins supports Organon Trustees through acquisition process - Marketing Stockport
Organon & Co (OGN) Institutional Confidence - TradingKey
Samsung Bioepis and Organon Expand Canadian Biosimilars Alliance with PYZCHIVA® Commercialisation Agreement - BioPharma APAC
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co.OGN - Business Wire
Organon launches BILDYOS and TUZEMTY Denosumab biosimilars in Canada - grafa.com
Henlius And Organon Deepen Canada’s Denosumab Biosimilar Race - Citeline News & Insights
Organon puts two Prolia, Xgeva biosimilars on sale in Canada - Stock Titan
Organon completes licensing deal for hormone-free IUD Miudella - Investing.com UK
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG) - GlobeNewswire Inc.
Organon secures global licensing deal for MIUDELLA copper IUD - grafa.com
Organon & Co. (OGN) is attracting investor attention: Here is what you should know - MSN
Organon To Commercialize Samsung Bioepis’ Stelara Biosimilar In Canada - insights.citeline.com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Organon completes licensing deal for hormone-free IUD Miudella By Investing.com - Investing.com Australia
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device - Business Wire
Lombard Odier Asset Management (USA) Corp's Organon & Co(OGN) Holding History - GuruFocus
Samsung Bioepis, Organon expand Stelara biosimilar partnership to Canada - koreabiomed.com
1.45%
大文字化:
|
ボリューム (24 時間):